Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
820 stopped studies mapped to Malignant Colorectal Neoplasm and descendants · 90% state a reason
Over the 820 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02614157 | Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal… | N/A | terminated | Nov 25, 2015 | West China Hospital | The enrollment was too low | Enrollment / accrual |
| NCT04664543 | Efficacy of Free Versus Low Residue Diet as Preparation for Screening Colonoscopy(CriLi) | N/A | terminated | Dec 11, 2020 | Parc Taulí Hospital Universitari | Organization and logistic problems due to COVID19 pandemy | COVID-19 / pandemic |
| NCT00578396 | Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer… | Phase 1 | withdrawn | Dec 21, 2007 | University of California, Irvine | Non applicable clinical trial | Other (stated, no rule matched) |
| NCT03149679 | The p53 Colorectal Cancer Trial | Phase 2 | terminated | May 11, 2017 | Haukeland University Hospital | The study was discontinued after the first pre-planned interim analysis due to insufficient… | Efficacy / futility |
| NCT03170115 | Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal…(ICAR) | Phase 2 | terminated | May 30, 2017 | Instituto Nacional de Cancer, Brazil | Aspirin added to chemoradiotherapy was safe but did not improve response to total neoadjuvant… | Other (stated, no rule matched) |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT03257332 | Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After…(EDFI-Cohort) | — | withdrawn | Aug 22, 2017 | Slagelse Hospital | Not possible to include participants | Other (stated, no rule matched) |
| NCT00023868 | Combination Chemotherapy With or Without Chemoembolization in Treating Patients With… | Phase 3 | terminated | Jun 17, 2003 | American College of Radiology Imaging Network | redesign | Other (stated, no rule matched) |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal… | Phase 1 / Phase 2 | withdrawn | Apr 1, 2010 | Imperial College London | Failure to recruit. | Enrollment / accrual |
| NCT00986440 | Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control… | Phase 2 | terminated | Sep 30, 2009 | Daiichi Sankyo | Due to changes to the standard of care within the proposed market for CS-7017. | Other (stated, no rule matched) |
| NCT03974984 | Anesthesia and Immunological and Oxidative Stress in Relation to Abdominal Cancer Surgery(ANIMOX) | — | withdrawn | Jun 5, 2019 | University of Copenhagen | Not feasable due to logistics | Other (stated, no rule matched) |
| NCT02010567 | Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer | Phase 1 / Phase 2 | terminated | Dec 12, 2013 | UNC Lineberger Comprehensive Cancer Center | The study was halted prematurely at the funding partner's request. | Funding |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin…(NeoFIND) | Phase 2 | terminated | Oct 30, 2018 | Advanced Accelerator Applications | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT00671645 | Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab,… | Phase 2 | terminated | May 5, 2008 | Austrian Breast & Colorectal Cancer Study Group | reaching of step 1 (recruitment of 8 patients) per protocol -\> risk assessment -\> termination… | Safety / toxicity |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03524274 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced… | Phase 2 | withdrawn | May 14, 2018 | Fuda Cancer Hospital, Guangzhou | No participants enrolled | Enrollment / accrual |
| NCT03549338 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | Phase 2 | terminated | Jun 8, 2018 | Symphogen A/S | Study was terminated due to administrative reasons | Other (stated, no rule matched) |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT03029988 | An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects… | Phase 1 | terminated | Jan 24, 2017 | Navidea Biopharmaceuticals | Lack of effect in Cohort 1 | Other (stated, no rule matched) |
| NCT01367275 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated… | Phase 2 | terminated | Jun 7, 2011 | M.D. Anderson Cancer Center | Sponsor closed study | Other (stated, no rule matched) |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT01302613 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or… | Phase 1 / Phase 2 | withdrawn | Feb 24, 2011 | University of Texas Southwestern Medical Center | Drug shortage | Other (stated, no rule matched) |
| NCT03035253 | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | Phase 1 | terminated | Jan 27, 2017 | OncoMed Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03448874 | Seal-G MIST (Minimally Invasive Sealant/Spray Technology) System Safety Study [SEALAR…(SEALAR) | N/A | withdrawn | Feb 28, 2018 | Sealantis Ltd. | The company will design a new study | Sponsor / business decision |
| NCT00740961 | Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer | — | terminated | Aug 25, 2008 | Case Comprehensive Cancer Center | low accrual | Enrollment / accrual |
| NCT02453490 | Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy… | Phase 3 | terminated | May 25, 2015 | Zhejiang University | difficultly recruiting | Enrollment / accrual |
| NCT02652702 | Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of…(STAPLER) | Phase 2 | terminated | Jan 12, 2016 | Zhejiang University | Not enough patients recruited | Enrollment / accrual |
| NCT04285008 | Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A…(RESCue) | N/A | withdrawn | Feb 26, 2020 | Motus GI Medical Technologies Ltd | Sponsor has terminated study due to COVID-19 related concerns | COVID-19 / pandemic |
| NCT02205307 | A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in…(PILLAR III) | N/A | terminated | Jul 31, 2014 | Novadaq Technologies ULC, now a part of Stryker | Slow recruitment | Enrollment / accrual |
| NCT03300609 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After… | Phase 3 | terminated | Oct 3, 2017 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT03258541 | Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy | N/A | terminated | Aug 23, 2017 | Thomas Zilli | Surgical access not facilitated- residues of hydrogel. | Other (stated, no rule matched) |
| NCT02052921 | Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved… | N/A | terminated | Feb 3, 2014 | Instituto do Cancer do Estado de São Paulo | During the execution time foreseen in the project, the expected number of patients was not reached. | Other (stated, no rule matched) |
| NCT00602329 | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab… | Phase 2 | terminated | Jan 28, 2008 | Abramson Cancer Center at Penn Medicine | Due to Poor accrual | Enrollment / accrual |
| NCT03705013 | Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01) | — | terminated | Oct 15, 2018 | Exact Sciences Corporation | Sponsor Decision | Sponsor / business decision |
| NCT03487484 | Quality of Life in Patients With Rectal Cancer Receiving Total Mesorectal Excision With… | — | terminated | Apr 4, 2018 | University Hospital, Basel, Switzerland | insufficient recruitment | Enrollment / accrual |
| NCT00353457 | Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally… | Phase 2 | terminated | Jul 18, 2006 | Abramson Cancer Center at Penn Medicine | new studies were finding that Erbitux was not beneficial | Other (stated, no rule matched) |
| NCT00091286 | Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal… | Early Phase 1 | terminated | Sep 9, 2004 | Craig L Slingluff, Jr | Slow accruals | Enrollment / accrual |
| NCT02889276 | Effects of Functional Exercise on Fitness and QoL in Cancer Survivors(RETRACE) | N/A | terminated | Sep 5, 2016 | University of Portsmouth | Only 4 participants were recruited from 130 potential participants. | Enrollment / accrual |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy…(UFT RT Phase 3) | Phase 3 | terminated | Sep 21, 2005 | Institut Cancerologie de l'Ouest | Terminated after interim analysis | Efficacy / futility |
| NCT01547923 | Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency…(DPD côlon) | N/A | terminated | Mar 8, 2012 | Institut Cancerologie de l'Ouest | The study stopped due to a death in the arm control | Other (stated, no rule matched) |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and…(McCAVE) | Phase 2 | terminated | May 19, 2014 | Hoffmann-La Roche | not stated | Not stated |
| NCT02797405 | Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay(THEODORA) | N/A | terminated | Jun 13, 2016 | Centre Leon Berard | Withdrawal of analysis study Partner. | Other (stated, no rule matched) |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | Phase 1 / Phase 2 | withdrawn | Mar 21, 2016 | Zhi Yang | Reform CAR structure due to safety consideration | Safety / toxicity |
| NCT03688230 | Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic…(AMELION) | Phase 2 | withdrawn | Sep 28, 2018 | SFJ Pharmaceuticals X, LTD. | Co-development decision | Other (stated, no rule matched) |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | terminated | Jan 5, 2012 | Georgetown University | Low accrual--unable to meet accrual goals | Enrollment / accrual |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | Phase 1 | withdrawn | Aug 23, 2018 | Lynkcell Inc. | Unable to recruit individuals for the study | Enrollment / accrual |
| NCT03049124 | Exercise for Adults Diagnosed With Rectal Cancer | N/A | withdrawn | Feb 9, 2017 | University of Ottawa | We were unable to enroll participants into the study. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 1, 2021source: clinicaltrials